Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dulaglutide + atorvastatin
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Subcutaneous (dulaglutide), Oral (atorvastatin)
01
Overview
This entry refers to a **combination of dulaglutide (formerly known as LY2189265)**, a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist, and **atorvastatin**, an HMG-CoA reductase inhibitor (statin). Dulaglutide improves glycemic control by stimulating insulin secretion and suppressing glucagon in a glucose-dependent manner, reducing blood glucose and aiding in weight management in type 2 diabetes. Atorvastatin lowers cholesterol by inhibiting endogenous cholesterol synthesis. This combination may be relevant for patients with type 2 diabetes who also require lipid-lowering therapy. The specific combination does not represent a co-formulated commercial product but has been studied in drug-drug interaction (DDI) research to assess any pharmacokinetic interactions or safety concerns when these agents are used together[1].
- Brand names
- Trulicity
- Other names
- LY2189265 + atorvastatin
02
Targets
GLP1R (GLP-1R)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on dulaglutide + atorvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dulaglutide + atorvastatin.